Buenos Aires , Argentina; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Santa Fe, Argentina; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Adelaide, Australia; Research Site:
OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Brisbane, Australia; Research Site:
OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Brisbane, Australia; Research Site:
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Carlton, Australia; Research Site:
OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Melbourne, Australia; Research Site:
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Melbourne, Australia; Research Site:
OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
South Yarra, Australia; Research Site:
OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
South Yarra, Australia; Research Site:
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Sydney, Australia; Research Site:
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Sydney, Australia; Research Site:
OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Westmead, Australia; Research Site:
OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
Bruxelles, Belgium; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Zaventem, Belgium; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Belo Horizonte, Brazil; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Campinas, Brazil; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Campinas, Brazil; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Nova Iguaçu, Brazil; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Porto Alegre, Brazil; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Porto Alegre, Brazil; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Porto Alegre, Brazil; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Ribeirão Preto, Brazil; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Rio De Janeiro, Brazil; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Rio De Janeiro, Brazil; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Salvador, Brazil; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Salvador, Brazil; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Salvador, Brazil; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Sao Paulo, Brazil; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Sao Paulo, Brazil; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Sao Paulo, Brazil; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Sofia, Bulgaria; Research Site:
A Study of Fuzeon (Enfuvirtide) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
Calgary, AB, Canada; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Calgary, AB, Canada; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Edmonton, AB, Canada; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Edmonton, AB, Canada; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Halifax, NS, Canada; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Hamilton, ON, Canada; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Hamilton, ON, Canada; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Montreal, QC, Canada; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Montreal, QC, Canada; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Montreal, QC, Canada; Research Site:
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Montreal, QC, Canada; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Montreal, QC, Canada; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Ottawa, ON, Canada; Research Site:
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Ottawa, ON, Canada; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Ottawa, ON, Canada; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Ottawa, ON, Canada; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Saskatoon, SK, Canada; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Saskatoon, SK, Canada; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Toronto, ON, Canada; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Toronto, ON, Canada; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Toronto, ON, Canada; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Toronto, ON, Canada; Research Site:
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Toronto, ON, Canada; Research Site:
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Vancouver, BC, Canada; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Vancouver, BC, Canada; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Århus, Denmark; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Hvidovre, Denmark; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
København, Denmark; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Odense, Denmark; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Argenteuil, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Aulnay Sous Bois, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Avignon, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Basse-Terre, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Basse-Terre, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Bobigny, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Bordeaux, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Bordeaux, France; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Bordeaux, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Boulogne, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Boulogne, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Caen, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Caen, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Colmar, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Creteil, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Fort-De-France, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Fort-De-France, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Garches, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Garches, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
La Roche Sur Yon, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Lagny-Sur-Marne, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Le Kremlin Bicêtre, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Levallois Perret, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Levallois Perret, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Lyon, France; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Lyon, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Lyon, France; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Marseille, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Marseille, France; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Marseille, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Montpellier, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Montpellier, France; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Nantes, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Nantes, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Nantes, France; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Nice, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Nice, France; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Nice, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Nimes, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Nimes, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Paris, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Paris, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Paris, France; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Paris, France; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Paris, France; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Paris, France; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Perpignan, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Pessac, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Pointe À Pitre, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Poitiers, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Poitiers, France; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Pontoise, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Pontoise, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Rennes, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Rouen, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Saint Pierre, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Saint Pierre, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Saint-Denis, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Saint-Denis, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Saint-Dizier, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Strasbourg, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Strasbourg, France; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Toulouse, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Toulouse, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Tourcoing, France; Research Site:
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Tourcoing, France; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Villejuif, France; Research Site:
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1)
Berlin, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Berlin, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Berlin, Germany; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Berlin, Germany; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Bochum, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Bonn, Germany; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Bremen, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Düsseldorf, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Essen, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Essen, Germany; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Frankfurt Am Main, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Frankfurt Am Main, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Frankfurt Am Main, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Grenzach-Wyhlen, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Hamburg, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Hamburg, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Hannover, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Hannover, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Heidelberg, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Koblenz, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Köln, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Köln, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Leipzig, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Mainz, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
München, Germany; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
München, Germany; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
München, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Nürnberg, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Osnabrück, Germany; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Osnabrück, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Stuttgart, Germany; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Alessandria, Italy; Research Site:
A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients
Asti, Italy; Research Site:
A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients
Bagno A Ripoli, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Benevento, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Brescia, Italy; Research Site:
A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients
Caserta, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Grosseto, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Lecco, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Milano, Italy; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Milano, Italy; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Milano, Italy; Research Site:
A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients
Milano, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Milano, Italy; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Monza, Italy; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Napoli, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Padova, Italy; Research Site:
A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients
Palermo, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Pavia, Italy; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Piacenza, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Roma, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Roma, Italy; Research Site:
A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients
Roma, Italy; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Siena, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Taranto, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Torino, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Udine, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Verbania, Italy; Research Site:
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients.
Mexico City, Mexico; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Mexico City, Mexico; Research Site:
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
Mexico City, Mexico; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Mexico City, Mexico; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Monterrey, Mexico; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Veracruz, Mexico; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Rotterdam, Netherlands; Research Site:
A Study of the Safety of Viracept (Nelfinavir) in an Expanded Access Program in HIV-1 Positive Women Who are Pregnant or Who Want to Become Pregnant.
Woerden, Netherlands; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Woerden, Netherlands; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Christchurch, New Zealand; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Warszawa, Poland; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Warszawa, Poland; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Amadora, Portugal; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Bucharest, Romania; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Constanta, Romania; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Alicante, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Alicante, Spain; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Barcelona, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Barcelona, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Barcelona, Spain; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Bilbao, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Bilbao, Spain; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Cádiz, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Madrid, Spain; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Madrid, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience
Madrid, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Santa Cruz de Tenerife, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Santander, Spain; Research Site:
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
Valencia, Spain; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Valencia, Spain; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Basel, Switzerland; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Bern, Switzerland; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Bern, Switzerland; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Geneve, Switzerland; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Geneve, Switzerland; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Lausanne, Switzerland; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Lausanne, Switzerland; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
Lugano, Switzerland; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Lugano, Switzerland; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
St. Gallen, Switzerland; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Zürich, Switzerland; Research Site:
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
Zürich, Switzerland; Research Site:
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
Bangkok, Thailand; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Bangkok, Thailand; Research Site:
A Study of Fuzeon (Enfuvirtide) in Patients With Advanced HIV Infection
Bangkok, Thailand; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Chiang Mai, Thailand; Research Site:
A Study of Fuzeon (Enfuvirtide) in Patients With Advanced HIV Infection
Khon Kaen, Thailand; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Nonthaburi, Thailand; Research Site:
A Study of Fuzeon (Enfuvirtide) in Patients With Advanced HIV Infection
Pathumwan, Thailand; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
Payathai, Thailand; Research Site:
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
London, United Kingdom; Research Site:
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection
